Skip to search formSkip to main contentSkip to account menu

andexanet

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Learning Objectives: Factor Xa inhibitors have gained popularity over vitamin K antagonists (VKAs) over the past years due to… 
2018
2018
Direct oral anticoagulants are becoming increasingly popular in outpatient use. These medications have lacked specific reversal… 
2017
2017
Recently, a study about andexanet for reversal of bleeding associated with factor Xa inhibitors has been published [1]. In this… 
Review
2017
Review
2017
Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient… 
Review
2017
Review
2017
This update reviews articles on nonmalignant hematology, malignant hematology, and medical oncology that were published in 2016… 
2016
2016
Until late 2010, the vitamin K antagonist warfarin was the only oral anticoagulant approved in the United States for the… 
2015
2015
Bleeding is a potential complication with factor Xa inhibitors, but two studies reported in the New England Journal of Medicine… 
2014
2014
Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big…